Logo
ホームページ
当社のモデルを探求してください。
カート
連絡先
購読する
モデル製品
HUGOシリーズ 🌟
HUGO-GT™(ヒト化ゲノムオルソログ)
HUGO-Ab™(抗体開発)
HUGO-Mab™ – 完全ヒトモノクローナル抗体マウス
MouseAtlas モデルライブラリ
期間限定セール
研究用動物モデル
Creマウス系統
ヒト化ターゲット遺伝子モデル
代謝疾患モデル
眼科疾患モデル
神経疾患モデル
自己免疫疾患モデル
免疫不全マウスモデル
ヒト化免疫系マウスモデル
腫瘍学・免疫腫瘍学モデル
新型コロナウイルス感染症(Covid-19)用マウスモデル
細胞株モデル
ノックアウト細胞株製品カタログ
iPS細胞株製品カタログ
腫瘍細胞株製品カタログ
AAV 标準製品カタログ
サービス
前臨床薬効評価
神経科学
アルツハイマー病前臨床CROサービス
パーキンソン病前臨床CROサービス
ハンチントン病前臨床CROサービス
血液脳関門(BBB)研究ソリューション
眼科分野
緑内障前臨床CROサービス
加齢黄斑変性(AMD)前臨床CROサービス
がん研究
PBMCヒト化マウスモデル
ヒト免疫システム(HIS)マウスモデル
代謝・循環器系疾患
抗肥満薬開発向け前臨床CROサービス
自己免疫・炎症疾患
喘息前臨床CROサービス
遺伝子改変動物
ノックアウトマウス
トランスジェニックマウス
ノックインマウス
ノックアウトラット
ノックインラット
トランスジェニックラット
遺伝子改変モデルの作製技術
TurboknockoutTMゲノム標的化技術
ターゲティング遺伝子編集
通常型トランスジェニック
PiggyBacトランスジェネシス
BACトランスジェニック
ES細胞ターゲティング
繁殖・サポートサービス
繫殖サービス
凍結保存および回復
表型解析サービス
BAC改変
ウイルスパッケージング
アデノ関連ウイルス(AAV)パッケージング
レントウイルスパッケージング
アデノウイルスパッケージング
カスタム細胞株作製サービス
誘導多能性幹細胞(iPS細胞)
ノックアウト細胞株
ノックイン細胞株
点変異細胞株
過剰発現細胞株
モダリティ
遺伝子治療
AI駆動型AAV開発
核酸医薬
細胞免疫療法
コミュ二ティー
キャンペーン
イベント・ウェビナー
ニュース
研究情報
資料室
データベース
査読済み文献(引用)
希少疾患データセンター
AbSeek
Cell iGeneEditor™ システム
OriCell 細胞培養関連
会社案内
企業概要
施設概要
動物の健康・福祉
健康報告書
協力企業・代理店
採用情報
お問い合わせ
Login
フィルター
フィルター
KO/cKO マウスモデル
フラッシュセール
HUGO-GT™ プラットフォーム
ヒト化ターゲット遺伝子モデル
ヒト化ターゲット遺伝子モデル
免疫ターゲットヒト化モデル腫瘍ターゲットヒト化モデル代謝ターゲットヒト化モデルサイトカインヒト化モデルその他のターゲットヒト化モデル
免疫系マウスモデル
免疫不全マウスモデルヒト化免疫系モデル
遺伝学ツールマウスモデル
Creドライバー系統レポーターマウス系統その他の遺伝学ツール系統
専門疾患モデル
眼科疾患モデル神経疾患モデル代謝疾患モデル腫瘍学・免疫腫瘍学モデル自己免疫疾患モデル希少疾患モデル感染症疾患モデルその他の疾患モデル
8 件の結果が “3105” で取得されました
フィルター
並べ替える:
アルファベット順(A-Z)
ベストセラー
H11-hB2M&HLA-A11
製品ID :
I001139
系統:
C57BL/6NCya
状況:
Live Mouse
説明:
The B2M gene encodes beta-2 microglobulin, a serum protein on the surface of nearly all nucleated cells along with the major histocompatibility complex (MHC) class I heavy chain. It is an essential component for transporting MHC class I proteins to the cell surface. Human leukocyte antigen (HLA), or the major histocompatibility complex (MHC), is a group of protein molecules on the surface of antigen-presenting cells responsible for antigen presentation. HLA mainly includes HLA class I, HLA class II, and HLA class III. HLA class I molecules (such as HLA-A, HLA-B, and HLA-C) primarily present antigens to CD8+ T cells and play a central role in the immune system. Through antigen presentation by HLA class I, the body can effectively recognize abnormal peptides, triggering targeted immune responses for immune clearance. Studies have shown that peptide vaccines composed of covalently linked minimal cytotoxic T lymphocyte (CTL) and T helper cell (TH) epitopes have significant effects in inducing cellular immune responses [1]. Due to species differences between mice and humans, and the varying ability of different HLA molecule subtypes to present different antigens, mouse-derived HLA cannot effectively simulate the immune response of human HLA subtypes. Therefore, constructing mice carrying human HLA genes helps to advance the study of HLA-restricted cytotoxic responses, such as identifying immunodominant HLA-restricted CTL epitopes and optimizing DNA vaccine constructs for human use [2-3]. HLA-A11 is one of the most common HLA class I alleles and is associated with infectious diseases (such as familial otosclerosis, pulmonary tuberculosis, and leprosy), tumors, and autoimmune diseases. The H11-hB2M&HLA-A11 mouse model is constructed by integrating the chimeric H2-K1 HLA-A11 gene into the H11 safe harbor locus of mice using gene editing technology. This mouse model can be used to identify viral peptides that express HLA-A11 binding sequences.
The B2M gene encodes beta-2 microglobulin, a serum protein on the surface of nearly all nucleated cells along with the major histocompatibility complex (MHC) class I heavy chain. It is an essential component for transporting MHC class I proteins to the cell surface. Human leukocyte antigen (HLA), or the major histocompatibility complex (MHC), is a group of protein molecules on the surface of antigen-presenting cells responsible for antigen presentation. HLA mainly includes HLA class I, HLA class II, and HLA class III. HLA class I molecules (such as HLA-A, HLA-B, and HLA-C) primarily present antigens to CD8+ T cells and play a central role in the immune system. Through antigen presentation by HLA class I, the body can effectively recognize abnormal peptides, triggering targeted immune responses for immune clearance. Studies have shown that peptide vaccines composed of covalently linked minimal cytotoxic T lymphocyte (CTL) and T helper cell (TH) epitopes have significant effects in inducing cellular immune responses [1]. Due to species differences between mice and humans, and the varying ability of different HLA molecule subtypes to present different antigens, mouse-derived HLA cannot effectively simulate the immune response of human HLA subtypes. Therefore, constructing mice carrying human HLA genes helps to advance the study of HLA-restricted cytotoxic responses, such as identifying immunodominant HLA-restricted CTL epitopes and optimizing DNA vaccine constructs for human use [2-3]. HLA-A11 is one of the most common HLA class I alleles and is associated with infectious diseases (such as familial otosclerosis, pulmonary tuberculosis, and leprosy), tumors, and autoimmune diseases. The H11-hB2M&HLA-A11 mouse model is constructed by integrating the chimeric H2-K1 HLA-A11 gene into the H11 safe harbor locus of mice using gene editing technology. This mouse model can be used to identify viral peptides that express HLA-A11 binding sequences.
H11-hB2M & HLA-A24
製品ID :
I001137
系統:
C57BL/6NCya
状況:
Live Mouse
説明:
The B2M gene encodes beta-2 microglobulin, a serum protein on the surface of nearly all nucleated cells along with the major histocompatibility complex (MHC) class I heavy chain. It is an essential component for transporting MHC class I proteins to the cell surface. Human leukocyte antigen (HLA), or the major histocompatibility complex (MHC), is a group of protein molecules on the surface of antigen-presenting cells responsible for antigen presentation. HLA mainly includes HLA class I, HLA class II, and HLA class III. HLA class I molecules (such as HLA-A, HLA-B, and HLA-C) primarily present antigens to CD8+ T cells and play a central role in the immune system. Through antigen presentation by HLA class I, the body can effectively recognize abnormal peptides, triggering targeted immune responses for immune clearance. Studies have shown that peptide vaccines composed of covalently linked minimal cytotoxic T lymphocyte (CTL) and T helper cell (TH) epitopes have significant effects in inducing cellular immune responses [1]. Due to species differences between mice and humans, and the varying ability of different HLA molecule subtypes to present different antigens, mouse-derived HLA cannot effectively simulate the immune response of human HLA subtypes. Therefore, constructing mice carrying human HLA genes helps to advance the study of HLA-restricted cytotoxic responses, such as identifying immunodominant HLA-restricted CTL epitopes and optimizing DNA vaccine constructs for human use [2-3]. HLA-A24 (A24) is a human leukocyte antigen of the HLA-A serotype group, with its alpha chain encoded by the HLA-A*24 allele and its beta chain encoded by the B2M gene. The H11-hB2M&HLA-A24 mouse model is constructed by integrating the chimeric H2-K1 HLA-A24 gene into the H11 safe harbor locus of mice using gene editing technology. This humanized model can be used to identify viral peptides that express HLA-A24 binding sequences.
The B2M gene encodes beta-2 microglobulin, a serum protein on the surface of nearly all nucleated cells along with the major histocompatibility complex (MHC) class I heavy chain. It is an essential component for transporting MHC class I proteins to the cell surface. Human leukocyte antigen (HLA), or the major histocompatibility complex (MHC), is a group of protein molecules on the surface of antigen-presenting cells responsible for antigen presentation. HLA mainly includes HLA class I, HLA class II, and HLA class III. HLA class I molecules (such as HLA-A, HLA-B, and HLA-C) primarily present antigens to CD8+ T cells and play a central role in the immune system. Through antigen presentation by HLA class I, the body can effectively recognize abnormal peptides, triggering targeted immune responses for immune clearance. Studies have shown that peptide vaccines composed of covalently linked minimal cytotoxic T lymphocyte (CTL) and T helper cell (TH) epitopes have significant effects in inducing cellular immune responses [1]. Due to species differences between mice and humans, and the varying ability of different HLA molecule subtypes to present different antigens, mouse-derived HLA cannot effectively simulate the immune response of human HLA subtypes. Therefore, constructing mice carrying human HLA genes helps to advance the study of HLA-restricted cytotoxic responses, such as identifying immunodominant HLA-restricted CTL epitopes and optimizing DNA vaccine constructs for human use [2-3]. HLA-A24 (A24) is a human leukocyte antigen of the HLA-A serotype group, with its alpha chain encoded by the HLA-A*24 allele and its beta chain encoded by the B2M gene. The H11-hB2M&HLA-A24 mouse model is constructed by integrating the chimeric H2-K1 HLA-A24 gene into the H11 safe harbor locus of mice using gene editing technology. This humanized model can be used to identify viral peptides that express HLA-A24 binding sequences.
H11-hB2M & HLA-A2.1
製品ID :
I001138
系統:
C57BL/6NCya
状況:
Live Mouse
説明:
The B2M gene encodes beta-2 microglobulin, a serum protein on the surface of nearly all nucleated cells along with the major histocompatibility complex (MHC) class I heavy chain. It is an essential component for transporting MHC class I proteins to the cell surface. Human leukocyte antigen (HLA), or the major histocompatibility complex (MHC), is a group of protein molecules on the surface of antigen-presenting cells responsible for antigen presentation. HLA mainly includes HLA class I, HLA class II, and HLA class III. HLA class I molecules (such as HLA-A, HLA-B, and HLA-C) primarily present antigens to CD8+ T cells and play a central role in the immune system. Through antigen presentation by HLA class I, the body can effectively recognize abnormal peptides, triggering targeted immune responses for immune clearance. Studies have shown that peptide vaccines composed of covalently linked minimal cytotoxic T lymphocyte (CTL) and T helper cell (TH) epitopes have significant effects in inducing cellular immune responses [1]. Due to species differences between mice and humans, and the varying ability of different HLA molecule subtypes to present different antigens, mouse-derived HLA cannot effectively simulate the immune response of human HLA subtypes. Therefore, constructing mice carrying human HLA genes helps to advance the study of HLA-restricted cytotoxic responses, such as identifying immunodominant HLA-restricted CTL epitopes and optimizing DNA vaccine constructs for human use [2-3]. HLA-A2.1 is a subtype of class I HLA and one of the most common HLA subtypes globally. The H11-hB2M&HLA-A2.1 mouse model is constructed by integrating the chimeric H2-K1 HLA-A2.1 gene into the H11 safe harbor locus of mice using gene editing technology. This humanized model can play a significant role in studying the determinants of HLA-A2.1-restricted cytotoxic T cells (CTLs) and in the development of potential viral vaccines.
The B2M gene encodes beta-2 microglobulin, a serum protein on the surface of nearly all nucleated cells along with the major histocompatibility complex (MHC) class I heavy chain. It is an essential component for transporting MHC class I proteins to the cell surface. Human leukocyte antigen (HLA), or the major histocompatibility complex (MHC), is a group of protein molecules on the surface of antigen-presenting cells responsible for antigen presentation. HLA mainly includes HLA class I, HLA class II, and HLA class III. HLA class I molecules (such as HLA-A, HLA-B, and HLA-C) primarily present antigens to CD8+ T cells and play a central role in the immune system. Through antigen presentation by HLA class I, the body can effectively recognize abnormal peptides, triggering targeted immune responses for immune clearance. Studies have shown that peptide vaccines composed of covalently linked minimal cytotoxic T lymphocyte (CTL) and T helper cell (TH) epitopes have significant effects in inducing cellular immune responses [1]. Due to species differences between mice and humans, and the varying ability of different HLA molecule subtypes to present different antigens, mouse-derived HLA cannot effectively simulate the immune response of human HLA subtypes. Therefore, constructing mice carrying human HLA genes helps to advance the study of HLA-restricted cytotoxic responses, such as identifying immunodominant HLA-restricted CTL epitopes and optimizing DNA vaccine constructs for human use [2-3]. HLA-A2.1 is a subtype of class I HLA and one of the most common HLA subtypes globally. The H11-hB2M&HLA-A2.1 mouse model is constructed by integrating the chimeric H2-K1 HLA-A2.1 gene into the H11 safe harbor locus of mice using gene editing technology. This humanized model can play a significant role in studying the determinants of HLA-A2.1-restricted cytotoxic T cells (CTLs) and in the development of potential viral vaccines.
H11-hB2M&HLA-A2.1/B2m-KO
製品ID :
C001696
系統:
C57BL/6N;6JCya
状況:
Live Mouse
説明:
The B2M gene encodes beta-2 microglobulin, a serum protein on the surface of nearly all nucleated cells along with the major histocompatibility complex (MHC) class I heavy chain. It is an essential component for transporting MHC class I proteins to the cell surface. Human leukocyte antigen (HLA), or the major histocompatibility complex (MHC), is a group of protein molecules on the surface of antigen-presenting cells responsible for antigen presentation. HLA mainly includes HLA class I, HLA class II, and HLA class III. HLA class I molecules (such as HLA-A, HLA-B, and HLA-C) primarily present antigens to CD8+ T cells and play a central role in the immune system. Through antigen presentation by HLA class I, the body can effectively recognize abnormal peptides, triggering targeted immune responses for immune clearance. Studies have shown that peptide vaccines composed of covalently linked minimal cytotoxic T lymphocyte (CTL) and T helper cell (TH) epitopes have significant effects in inducing cellular immune responses [1]. Due to species differences between mice and humans, and the varying ability of different HLA molecule subtypes to present different antigens, mouse-derived HLA cannot effectively simulate the immune response of human HLA subtypes. Therefore, constructing mice carrying human HLA genes helps to advance the study of HLA-restricted cytotoxic responses, such as identifying immunodominant HLA-restricted CTL epitopes and optimizing DNA vaccine constructs for human use [2-3]. HLA-A2.1 is a subtype of class I HLA and is one of the most common HLA subtypes worldwide. HLA-A2.1 plays an important role in the immune system, especially in the presentation of antigens such as viruses, bacteria, and parasites to cytotoxic T cells (CD8+ T cells). This presentation process is essential for the immune response of the human body to a variety of pathogens, particularly in the response to human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV). In addition, HLA-A2.1 is also involved in the immune response to cancer cells, further emphasizing its importance in the human immune system. The H11-hB2M&HLA-A2.1/B2m-KO mice are a humanized model obtained by mating H11-hB2M&HLA-A2.1 mice (Catalog Number: I001138) with the B2m gene knockout mouse model (Catalog Number: S-KO-19919). While knocking out the mouse B2m gene, the chimeric H2-K1 HLA-A2.1 gene is integrated into the H11 safe harbor locus, which may be able to recapitulate the immune response of the human HLA-A*0201 (MHCI) subtype. This model can play an important role in studying the determinants of HLA-A2.1-restricted cytotoxic T lymphocytes (CTLs) and the development of potential viral vaccines and helps research the human immune response to a variety of antigens.
The B2M gene encodes beta-2 microglobulin, a serum protein on the surface of nearly all nucleated cells along with the major histocompatibility complex (MHC) class I heavy chain. It is an essential component for transporting MHC class I proteins to the cell surface. Human leukocyte antigen (HLA), or the major histocompatibility complex (MHC), is a group of protein molecules on the surface of antigen-presenting cells responsible for antigen presentation. HLA mainly includes HLA class I, HLA class II, and HLA class III. HLA class I molecules (such as HLA-A, HLA-B, and HLA-C) primarily present antigens to CD8+ T cells and play a central role in the immune system. Through antigen presentation by HLA class I, the body can effectively recognize abnormal peptides, triggering targeted immune responses for immune clearance. Studies have shown that peptide vaccines composed of covalently linked minimal cytotoxic T lymphocyte (CTL) and T helper cell (TH) epitopes have significant effects in inducing cellular immune responses [1]. Due to species differences between mice and humans, and the varying ability of different HLA molecule subtypes to present different antigens, mouse-derived HLA cannot effectively simulate the immune response of human HLA subtypes. Therefore, constructing mice carrying human HLA genes helps to advance the study of HLA-restricted cytotoxic responses, such as identifying immunodominant HLA-restricted CTL epitopes and optimizing DNA vaccine constructs for human use [2-3]. HLA-A2.1 is a subtype of class I HLA and is one of the most common HLA subtypes worldwide. HLA-A2.1 plays an important role in the immune system, especially in the presentation of antigens such as viruses, bacteria, and parasites to cytotoxic T cells (CD8+ T cells). This presentation process is essential for the immune response of the human body to a variety of pathogens, particularly in the response to human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV). In addition, HLA-A2.1 is also involved in the immune response to cancer cells, further emphasizing its importance in the human immune system. The H11-hB2M&HLA-A2.1/B2m-KO mice are a humanized model obtained by mating H11-hB2M&HLA-A2.1 mice (Catalog Number: I001138) with the B2m gene knockout mouse model (Catalog Number: S-KO-19919). While knocking out the mouse B2m gene, the chimeric H2-K1 HLA-A2.1 gene is integrated into the H11 safe harbor locus, which may be able to recapitulate the immune response of the human HLA-A*0201 (MHCI) subtype. This model can play an important role in studying the determinants of HLA-A2.1-restricted cytotoxic T lymphocytes (CTLs) and the development of potential viral vaccines and helps research the human immune response to a variety of antigens.
NKG-H11-hB2M&HLA-A2.1
製品ID :
C001844
系統:
NKG
状況:
Live Mouse
説明:
NKG mice are a type of severe immunodeficient mouse developed by Cyagen by deleting the Il2rg gene from the NOD-Scid strain. This strain lacks mature T, B, and NK cells, exhibits reduced complement activity, and weak macrophage phagocytosis of human cells. As a result, NKG mice can efficiently engraft human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), patient-derived xenografts (PDX), or adult stem cells and tissues. In immunology research, direct studies on mice may not fully represent the human immune system due to physiological and immune system differences. However, by transplanting human peripheral blood mononuclear cells (PBMCs) or hematopoietic stem cells (HSCs) into immunodeficient mice, we can partially or completely replace the mouse immune system with a human counterpart. This approach enables in vivo simulation of human immune system function, providing an effective model for studying human immunity. However, in actual human-mouse xenotransplantation, due to the lack of specific human cytokines and supportive stromal cells in mice, transplantation using conventional immunodeficient mice is likely to result in variations in immune reconstitution efficiency. Modifying immunodeficient mice via gene editing technology to establish a humanized immune microenvironment in mice and promote the functional maturation of human-derived cells is a universal strategy for improving the efficiency of immune reconstitution in xenotransplantation. The B2M gene encodes beta-2 microglobulin, a serum protein on the surface of nearly all nucleated cells along with the major histocompatibility complex (MHC) class I heavy chain. It is an essential component for transporting MHC class I proteins to the cell surface. Human leukocyte antigen (HLA), or the major histocompatibility complex (MHC), is a group of protein molecules on the surface of antigen-presenting cells responsible for antigen presentation. HLA mainly includes HLA class I, HLA class II, and HLA class III. HLA class I molecules (such as HLA-A, HLA-B, and HLA-C) primarily present antigens to CD8+ T cells and play a central role in the immune system. Through antigen presentation by HLA class I, the body can effectively recognize abnormal peptides, triggering targeted immune responses for immune clearance. Studies have shown that peptide vaccines composed of covalently linked minimal cytotoxic T lymphocyte (CTL) and T helper cell (TH) epitopes have significant effects in inducing cellular immune responses [1]. Due to species differences between mice and humans, and the varying ability of different HLA molecule subtypes to present different antigens, mouse-derived HLA cannot effectively simulate the immune response of human HLA subtypes. Therefore, constructing mice carrying human HLA genes helps to advance the study of HLA-restricted cytotoxic responses, such as identifying immunodominant HLA-restricted CTL epitopes and optimizing DNA vaccine constructs for human use [2-3]. NKG-H11-hB2M&HLA-A2.1 mouse is a model constructed via gene editing technology, in which the H2-K1 chimeric HLA-A2.1 gene is knocked into the H11 locus of mice on the NKG strain background. Compared with NKG mice, NKG-H11-hB2M&HLA-A2.1 mice generate functional human T cell subsets with HLA-restricted immune responses after hematopoietic stem cell (HSC) transplantation. Human cytotoxic T lymphocytes (CTLs) developed in immunologically reconstituted mice recognize pathogens in an HLA-restricted manner and exert HLA-restricted cytotoxicity against infected human B cells [4]. This model provides an ideal platform for investigating human immune responses to pathogens, HLA-restricted cytotoxic responses, and related research areas.
NKG mice are a type of severe immunodeficient mouse developed by Cyagen by deleting the Il2rg gene from the NOD-Scid strain. This strain lacks mature T, B, and NK cells, exhibits reduced complement activity, and weak macrophage phagocytosis of human cells. As a result, NKG mice can efficiently engraft human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), patient-derived xenografts (PDX), or adult stem cells and tissues. In immunology research, direct studies on mice may not fully represent the human immune system due to physiological and immune system differences. However, by transplanting human peripheral blood mononuclear cells (PBMCs) or hematopoietic stem cells (HSCs) into immunodeficient mice, we can partially or completely replace the mouse immune system with a human counterpart. This approach enables in vivo simulation of human immune system function, providing an effective model for studying human immunity. However, in actual human-mouse xenotransplantation, due to the lack of specific human cytokines and supportive stromal cells in mice, transplantation using conventional immunodeficient mice is likely to result in variations in immune reconstitution efficiency. Modifying immunodeficient mice via gene editing technology to establish a humanized immune microenvironment in mice and promote the functional maturation of human-derived cells is a universal strategy for improving the efficiency of immune reconstitution in xenotransplantation. The B2M gene encodes beta-2 microglobulin, a serum protein on the surface of nearly all nucleated cells along with the major histocompatibility complex (MHC) class I heavy chain. It is an essential component for transporting MHC class I proteins to the cell surface. Human leukocyte antigen (HLA), or the major histocompatibility complex (MHC), is a group of protein molecules on the surface of antigen-presenting cells responsible for antigen presentation. HLA mainly includes HLA class I, HLA class II, and HLA class III. HLA class I molecules (such as HLA-A, HLA-B, and HLA-C) primarily present antigens to CD8+ T cells and play a central role in the immune system. Through antigen presentation by HLA class I, the body can effectively recognize abnormal peptides, triggering targeted immune responses for immune clearance. Studies have shown that peptide vaccines composed of covalently linked minimal cytotoxic T lymphocyte (CTL) and T helper cell (TH) epitopes have significant effects in inducing cellular immune responses [1]. Due to species differences between mice and humans, and the varying ability of different HLA molecule subtypes to present different antigens, mouse-derived HLA cannot effectively simulate the immune response of human HLA subtypes. Therefore, constructing mice carrying human HLA genes helps to advance the study of HLA-restricted cytotoxic responses, such as identifying immunodominant HLA-restricted CTL epitopes and optimizing DNA vaccine constructs for human use [2-3]. NKG-H11-hB2M&HLA-A2.1 mouse is a model constructed via gene editing technology, in which the H2-K1 chimeric HLA-A2.1 gene is knocked into the H11 locus of mice on the NKG strain background. Compared with NKG mice, NKG-H11-hB2M&HLA-A2.1 mice generate functional human T cell subsets with HLA-restricted immune responses after hematopoietic stem cell (HSC) transplantation. Human cytotoxic T lymphocytes (CTLs) developed in immunologically reconstituted mice recognize pathogens in an HLA-restricted manner and exert HLA-restricted cytotoxicity against infected human B cells [4]. This model provides an ideal platform for investigating human immune responses to pathogens, HLA-restricted cytotoxic responses, and related research areas.
Mag-KO
製品ID :
S-KO-03105
系統:
C57BL/6JCya
状況:
Frozen Sperm
説明:
Mag is located on chromosome 7 of mice. Nuclease Technology was used to design sgRNA; Mag knockout mice were obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Mag is located on chromosome 7 of mice. Nuclease Technology was used to design sgRNA; Mag knockout mice were obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Il4ra-flox
製品ID :
S-CKO-03105
系統:
C57BL/6JCya
状況:
Frozen Sperm
説明:
Il4ra is located on chromosome 7 of mice. SgRNA and ssDNA were designed using Nuclease Technology; Il4ra conditional knockout mice were obtained by high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Il4ra is located on chromosome 7 of mice. SgRNA and ssDNA were designed using Nuclease Technology; Il4ra conditional knockout mice were obtained by high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
B6-hCD3/H11-hB2M&HLA-A2.1
製品ID :
I001207
系統:
C57BL/6NCya
状況:
Live Mouse
説明:
Cluster of Differentiation 3 (CD3) is a protein complex that functions as a co-receptor on T cells, playing a critical role in the activation of cytotoxic T lymphocytes (CTLs) and helper T cells (THs). CD3 comprises five transmembrane polypeptide chains—γ, δ, ε, ζ, and η—each contributing to the structural integrity and signaling capacity of the complex. The transmembrane domains of CD3 form salt bridges with the transmembrane regions of the T cell receptor (TCR) α and β chains, assembling into the TCR-CD3 complex that mediates antigen recognition by T cells [1-2]. Upon antigen engagement by the TCR, activation signals are transduced intracellularly via CD3. CD3 is expressed with high specificity throughout all stages of T cell development and is therefore widely utilized as an immunohistochemical marker for T cell identification. Moreover, CD3 is present in nearly all T cell lymphomas and leukemias, enabling differential diagnosis from morphologically similar B cell and myeloid malignancies. Given its pivotal role in T cell activation and antigen recognition, CD3 has emerged as a key therapeutic target in immunosuppressive strategies for type 1 diabetes and other autoimmune disorders [3]. The B2M gene encodes β2-microglobulin, a serum protein that associates with the heavy chain of major histocompatibility complex (MHC) class I molecules and is essential for their surface expression on virtually all nucleated cells. Human leukocyte antigens (HLAs), also referred to as MHC molecules, are cell-surface proteins responsible for antigen presentation. The HLA system comprises class I, class II, and class III molecules. HLA class I molecules—including HLA-A, HLA-B, and HLA-C—primarily present antigens to CD8⁺ T cells and are central to immune surveillance. Through HLA class I–mediated antigen presentation, the immune system can detect aberrant peptides and initiate targeted cytotoxic responses for immune clearance. HLA-A2.1 is a subtype of HLA class I and represents one of the most prevalent HLA alleles worldwide. The B6-hCD3/H11-hB2M&HLA-A2.1 mouse model is generated by crossing B6-hCD3 mice (catalog no. C001325) with H11-hB2M&HLA-A2.1 mice (catalog no. I001138). These mice co-express human CD3, human β2-microglobulin, and HLA-A0201 proteins in vivo. This model enables mechanistic investigation of T cell activation, antigen recognition, and antigen presentation, and serves as a versatile platform for evaluating immunosuppressive therapies in autoimmune diseases, studying human viral infections, and developing and testing novel viral vaccines.
Cluster of Differentiation 3 (CD3) is a protein complex that functions as a co-receptor on T cells, playing a critical role in the activation of cytotoxic T lymphocytes (CTLs) and helper T cells (THs). CD3 comprises five transmembrane polypeptide chains—γ, δ, ε, ζ, and η—each contributing to the structural integrity and signaling capacity of the complex. The transmembrane domains of CD3 form salt bridges with the transmembrane regions of the T cell receptor (TCR) α and β chains, assembling into the TCR-CD3 complex that mediates antigen recognition by T cells [1-2]. Upon antigen engagement by the TCR, activation signals are transduced intracellularly via CD3. CD3 is expressed with high specificity throughout all stages of T cell development and is therefore widely utilized as an immunohistochemical marker for T cell identification. Moreover, CD3 is present in nearly all T cell lymphomas and leukemias, enabling differential diagnosis from morphologically similar B cell and myeloid malignancies. Given its pivotal role in T cell activation and antigen recognition, CD3 has emerged as a key therapeutic target in immunosuppressive strategies for type 1 diabetes and other autoimmune disorders [3]. The B2M gene encodes β2-microglobulin, a serum protein that associates with the heavy chain of major histocompatibility complex (MHC) class I molecules and is essential for their surface expression on virtually all nucleated cells. Human leukocyte antigens (HLAs), also referred to as MHC molecules, are cell-surface proteins responsible for antigen presentation. The HLA system comprises class I, class II, and class III molecules. HLA class I molecules—including HLA-A, HLA-B, and HLA-C—primarily present antigens to CD8⁺ T cells and are central to immune surveillance. Through HLA class I–mediated antigen presentation, the immune system can detect aberrant peptides and initiate targeted cytotoxic responses for immune clearance. HLA-A2.1 is a subtype of HLA class I and represents one of the most prevalent HLA alleles worldwide. The B6-hCD3/H11-hB2M&HLA-A2.1 mouse model is generated by crossing B6-hCD3 mice (catalog no. C001325) with H11-hB2M&HLA-A2.1 mice (catalog no. I001138). These mice co-express human CD3, human β2-microglobulin, and HLA-A0201 proteins in vivo. This model enables mechanistic investigation of T cell activation, antigen recognition, and antigen presentation, and serves as a versatile platform for evaluating immunosuppressive therapies in autoimmune diseases, studying human viral infections, and developing and testing novel viral vaccines.
Items: 1 to 8 of 8
1
さらに
すべてのフィルター
Strain Type
Mouse
Rat
Modification Type
Knockout
Conditional Knockout
Knockin
Point Mutation
Transgenic
Conditional Knockin
Others
Status
Live Mice
R&D
Frozen Sperm
Validation Data
Verified
In Progress
リセット
確認する
モデルライブラリ
モデルライブラリ
リソース
リソース
動物の品質
動物の品質
サポートを受ける
サポートを受ける
住所:
〒543-0071 大阪府大阪市天王寺区生玉町2-3 小出ビル410室
電話 :
06-7652-3321
メール:
[email protected]
モデル製品
HUGO-Ab™(抗体開発)HUGO-GT™(ヒト化ゲノムオルソログ)MouseAtlas モデルライブラリ研究用動物モデル
サービス
神経科学眼科分野がん研究代謝・循環器系疾患自己免疫・炎症疾患
会社案内
企業概要施設概要動物の健康・福祉健康報告書協力企業・代理店採用情報お問い合わせ
SNS
免責事項:当社の製品およびサービスの価格や入手可能性は地域によって異なります。記載されている価格は特定の国々に適用されます。詳細についてはご連絡ください。
Copyright © 2025 Cyagen. All rights reserved.
プライバシーポリシー
サイトマップ
Cyagenの最新情報をお届けします
研究モデル、CROサービス、科学リソース、特別オファーに関する最新情報を、研究ニーズに合わせてメールでお届けします。
お名前
メール
ご所属機関
関心分野
主な研究分野